Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to estimate the R0 resection rate in patients with Resectable
Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal
Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of
combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
Phase:
Phase 2
Details
Lead Sponsor:
Academic Thoracic Oncology Medical Investigators Consortium University of Colorado, Denver
Collaborators:
Celgene Corporation Criterium, Inc. University of Colorado, Denver